Miltenyi Biotec Opens a New Office in South Korea

Press Releases »

BERGISCH GLADBACH, Germany--27 Jun--PRNewswire/ InfoQuest


Miltenyi Biotec, the world's leading cell innovation company, announced today that it opened a new office in Seoul, Korea, enlarging the company's Asia-Pacific presence to six locations in five countries.

"Miltenyi Biotec recognizes the potential of a Korean presence in achieving strong, steady growth and expanding our global reach with a team of talented people," said CEO Boris Stoffel. "Our new team has an exceptional ability to partner with scientists and clinicians to generate exciting opportunities."

Daesuk Oh has been appointed General Manager of the new office in the Gangnam district of Seoul. "Our location will be instrumental in developing deeper relationships with a host of stem cell, immunology, translational research, and clinical customers, as well as prospective research and clinical institutions throughout South Korea. We're excited for the opportunity to bring Miltenyi Biotec's solutions to scientists and clinicians who can truly benefit from the quality and reliability the portfolio is known for," said Oh.

About Miltenyi Biotec

Miltenyi Biotec is a global provider of products and services that advance biomedical research. From research tools to GMP reagents, Miltenyi is making the promise of cell therapy a reality. The company's integrated portfolio of tools supports the translation of basic research into practical applications for human health. Scientists and clinicians around the world use Miltenyi-enabling technologies for effective sample preparation, cell isolation, flow cytometry, cell culture, molecular analysis and preclinical imaging. The MACS(R) brand has set standards in the industry and is trusted across basic, translational, and clinical research settings. The company also offers comprehensive technical support and training through its MACS(R) Academy. Miltenyi Biotec has 1,400 employees in 22 countries.

Media Contact:

Prof. Dr. Uwe Heinlein

Phone: +49-2204-8306-6590

E-mail: [email protected]

http://www.miltenyibiotec.com

Source: Miltenyi Biotec GmbH

-PP-

ข่าวMiltenyi Biotec+the companyวันนี้

Alibaba Maintains Leading Position by Revenue as Asia Pacific's Largest Cloud Provider with Growing Market Share

Alibaba Cloud, the digital technology and intelligence backbone of Alibaba Group, has once again been recognised as the largest cloud Infrastructure-as-a-Service (IaaS) provider by revenue in Asia Pacific, with its regional market share increasing to 22.5% in 2025, up from 20.8% in 2024. The findings come from the latest Gartner(R) report, Market Share: IaaS, Worldwide, 2025, 10 April 2026. Alibaba Cloud 's continued leadership across Asia Pacific reflects the company's sustained investment in

The Creators HQ Marks a Decade of Design-... The Creators HQ Marks a Decade of Design-Led Living — The Creators HQ Marks a Decade of Design-Led Living, Setting Its Sights on THB 1 Billion Revenue in...

Metro Connect Co., Ltd. (MCC) has joined ... MCC Teams Up with HPE and Elastic for Partner Connect Event to Boost Digital Transformation — Metro Connect Co., Ltd. (MCC) has joined forces with Hewlett...

Perfect Tailor, one of Sukhumvit's most e... Perfect Tailor Celebrates 25 Years of Crafting Bespoke Fashion in Bangkok — Perfect Tailor, one of Sukhumvit's most established tailoring houses, celebrat...

Strategic joint venture marks Centara's e... Centara Hotels & Resorts and OR partner to Launch New Budget Hotel Brand — Strategic joint venture marks Centara's entry into the budget hotel segment...

Miltenyi Biotec ประกาศเปิดตัวผลิตภัณฑ์ตระกูล Viscover(TM) สำหรับการสร้างภาพภายในร่างกายสัตว์ขนาดเล็ก

Miltenyi Biotec ประกาศการเปิดตัวทั่วโลกสำหรับผลิตภัณฑ์ตระกูล Viscover(TM) ซึ่งเป็นสารทึบรังสี (contrast agents) ที่ฉีดเข้าไปในร่างกายเพื่อช่วยให้นักวิจัยเห็นภาพภายในร่างกายของสัตว์ขนาดเล็กได้อย่างชัด...

Miltenyi Biotec Announces Release of Viscover(TM) Preclinical Contrast Agents for in vivo Small Animal Imaging

Miltenyi Biotec today announces the worldwide release of the Viscover(TM) product line, offering researchers an unrivaled range of preclinical contrast agents for small animal in vivo...